Clinical trial • Phase III • Musculoskeletal
Baricitinib for Juvenile idiopathic arthritis
Phase III trial of Baricitinib for Juvenile idiopathic arthritis. None/Not specified-controlled. 101 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Juvenile idiopathic arthritis
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 28-02-2024
- First CTIS Authorization Date
- 04-04-2024
Trial design
None/Not specified-controlled Phase III trial in Austria, Belgium, Czechia and others.
- Comparator
- None/Not specified
- Target Sample Size
- 101
Eligibility
Recruits 101 paediatric patients.
- Vulnerable Population
- Vulnerable population selected: paediatric participants (ages 1 year to <18 years). Assent and parent/guardian consent materials are provided (documents include L1_SIS and ICF Parents, L1_SIS and ICF Assent forms for older and younger children, and age-specific ICFs such as L1_SIS and ICF 16 Plus_PL).
Inclusion criteria
- {"criterion_text":"- Participants must have completed a previous study of baricitinib for the treatment of JIA"}
- {"criterion_text":"- Participants must have not developed an allergy to baricitinib"}
Exclusion criteria
- {"criterion_text":"- Participants must not have permanently stopped baricitinib in the prior study"}
- {"criterion_text":"- Participants must have not developed an allergy to baricitinib"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Number of participants with one or more SAEs","definition_or_measurement_approach":""}
- {"endpoint_text":"- Number of participants with permanent investigational product discontinuations","definition_or_measurement_approach":""}
Recruitment
- Registry Or Advocacy Recruitment
- Yes
- Planned Sample Size
- 101
- Recruitment Window Months
- 133
- Consent Approach
- Parent/guardian informed consent and child assent processes are used for paediatric participants. Multiple age-specific consent and assent documents are listed (e.g. L1_SIS and ICF Main ICF in various languages, L1_SIS and ICF Parents, L1_SIS and ICF Assent form Older Children, L1_SIS and ICF Assent form Younger Children, country-specific ICFs such as PL and ES versions). Documents in the file list indicate availability in English, French, Dutch, Polish and Spanish; consent is provided by parent/guardian with assent from children as appropriate by age.
Methods
- Publicis Healthcare Communications Group Limited - Patient Screening, Recruitment, and/or Retention (documented duty)
- Pediatric Rheumatology International Trials Organization (PRINTO) - Patient Screening, Recruitment, and/or Retention (documented duty)
- Signant Health LLC - listed as third party with responsibilities (digital/electronic vendor listed) (no explicit recruitment channel described in documents)
- IQVIA Rds Inc. - listed as third party (no explicit recruitment channel described in documents)
- Icon Clinical Research Limited - listed as third party (no explicit recruitment channel described in documents)
- Other CRO/clinical research partners listed (Fortrea Inc., Macrostat (Shanghai) Clinical Research Co. Ltd., Q2 Solutions, Brightech International LLC) - listed as third parties; specific recruitment channels not described
Geography
- Total Number Of Sites
- 38
- Total Number Of Participants
- 101
Austria
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 09-04-2024
- Processing Time Days
- 29
- Number Of Sites
- 2
Sites
- Site Name
- LKH Bregenz
- Department Name
- Department of Pediatrics and Adolescent Medicine
- Contact Person Name
- Christian Huemer
- Contact Person Email
- christian.huemer@lkhb.at
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Pediatrics and Adolescent Medicine
- Contact Person Name
- Wolfgang Emminger
- Contact Person Email
- wolfgang.emminger@meduniwien.ac.at
Belgium
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 15-04-2024
- Processing Time Days
- 35
- Number Of Sites
- 3
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- Pediatric rheumatology
- Contact Person Name
- Joke Dehoorne
- Contact Person Email
- joke.dehoorne@uzgent.be
- Site Name
- Cliniques Universitaires Saint-Luc
- Department Name
- Hematology oncology pediatric
- Contact Person Name
- Cecile Boulanger
- Contact Person Email
- cecile.boulanger@saintluc.uclouvain.be
- Site Name
- UZ Leuven
- Department Name
- Kinderreumatologie
- Contact Person Name
- Lien De Somer
- Contact Person Email
- lien.desomer@uzleuven.be
Czechia
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 05-04-2024
- Processing Time Days
- 25
- Number Of Sites
- 4
Sites
- Site Name
- Vseobecna Fakultni Nemocnice V Praze
- Department Name
- reumatology
- Contact Person Name
- Pavla Dolezalova
- Contact Person Email
- pavla.dolezalova@vfn.cz
- Site Name
- University Hospital Olomouc
- Department Name
- reumatology
- Contact Person Name
- Kateřina Bouchalová
- Contact Person Email
- katerina.bouchalova@fnol.cz
- Site Name
- Fakultni Nemocnice Brno
- Department Name
- reumatology
- Contact Person Name
- Marcel Schüller
- Contact Person Email
- schullerm@email.cz
- Site Name
- Fakultni Nemocnice V Motole
- Department Name
- reumatology
- Contact Person Name
- Rudolf Horváth
- Contact Person Email
- rudolf.horvath@fnmotol.cz
Denmark
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 05-04-2024
- Processing Time Days
- 25
- Number Of Sites
- 2
Sites
- Site Name
- Aarhus Universitetshospital
- Contact Person Name
- Mia Glerup
- Contact Person Email
- miagleru@rm.dk
- Site Name
- Rigshospitalet
- Department Name
- BørneUngeAfdelingen
- Contact Person Name
- Charlotte Myrup
- Contact Person Email
- charlotte.myrup@regionh.dk
France
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 24-04-2024
- Processing Time Days
- 44
- Number Of Sites
- 5
Sites
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- RHUMATOLOGIE
- Contact Person Name
- Elisabeth Gervais
- Contact Person Email
- elisabeth.gervais@chu-poitiers.fr
- Site Name
- Bicetre Hospital
- Department Name
- Rhumatologie pediatrique et CEREMAIA
- Contact Person Name
- Isabelle Kone-Paut
- Contact Person Email
- isabelle.kone-paut@aphp.fr
- Site Name
- Hopital Necker Enfants Malades
- Department Name
- Unite d'Immunologie-Hematologie et Rhumatologie Pediatriques
- Contact Person Name
- Pierre Quartier Dit Maire
- Contact Person Email
- pierre.quartier@aphp.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Hospices Civils de Lyon - Hôpital Femme Mère Enfant
- Contact Person Name
- Alexandre Belot
- Contact Person Email
- alexandre.belot@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Nimes
- Department Name
- Service de pédiatrie
- Contact Person Name
- Tu-Anh Tran
- Contact Person Email
- tu.anh.tran@chu-nimes.fr
Germany
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 09-04-2024
- Processing Time Days
- 29
- Number Of Sites
- 5
Sites
- Site Name
- Universitaetsklinikum Tuebingen AöR
- Contact Person Name
- Jasmin Kuemmerle-Deschner
- Contact Person Email
- jasmin.kuemmerle-deschner@med.uni-tuebingen.de
- Site Name
- HELIOS Klinikum Berlin-Buch GmbH
- Contact Person Name
- Ralf Trauzeddel
- Contact Person Email
- ralf.trauzeddel@helios-gesundheit.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Contact Person Name
- Kirsten Minden
- Contact Person Email
- kirsten.minden@charite.de
- Site Name
- Asklepios Klinik Sankt Augustin GmbH
- Contact Person Name
- Gerd Horneff
- Contact Person Email
- g.horneff@asklepios.com
- Site Name
- Zentrum für Kinder- und Jugendrheumatologie
- Contact Person Name
- Ivan Foeldvari
- Contact Person Email
- foeldvari@t-online.de
Italy
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 15-05-2024
- Processing Time Days
- 65
- Number Of Sites
- 8
Sites
- Site Name
- ARNAS Civico di Cristina Benfratelli
- Department Name
- Dipartimento di Pediatria
- Contact Person Name
- Maria Cristina Maggio
- Contact Person Email
- mariacristina.maggio3@gmail.com
- Site Name
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
- Department Name
- UOC PEDIATRIA MEDIA INTENSITA' DI CURA
- Contact Person Name
- Giovanni Filocamo
- Contact Person Email
- giovanni.filocamo@policlinico.mi.it
- Site Name
- Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
- Department Name
- Clinica Pediatrica
- Contact Person Name
- Marco Cattalini
- Contact Person Email
- marco.cattalini@unibs.it
- Site Name
- Giannina Gaslini Institute For Scientific Hospitalization And Care
- Department Name
- U.O.C. Clinica Pediatrica e Reumatologia
- Contact Person Name
- Roberta Caorsi
- Contact Person Email
- robertacaorsi@gaslini.org
- Site Name
- Azienda Sanitaria Locale 2 Lanciano Vasto Chieti
- Department Name
- UOSD di Pediatria ad indirizzo reumatologico
- Contact Person Name
- Luciana Breda
- Contact Person Email
- luciana.bredach@gmail.com
- Site Name
- Centro Specialistico Ortopedico Traumatologico Gaetano Pini - CTO
- Department Name
- Reumatologia Pediatrica
- Contact Person Name
- Achille Marino
- Contact Person Email
- achille.marino@asst-pini-cto.it
- Site Name
- Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo
- Department Name
- Clinica Pediatrica
- Contact Person Name
- Alberto Tommasini
- Contact Person Email
- alberto.tommasini@burlo.trieste.it
- Site Name
- Azienda Ospedaliera Universitaria Federico II Di Napoli
- Department Name
- Dipartimento Scienze Mediche Traslazionali
- Contact Person Name
- Maria Alessio
- Contact Person Email
- mariolina.alessio@gmail.com
Poland
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 19-04-2024
- Processing Time Days
- 39
- Number Of Sites
- 3
Sites
- Site Name
- CSK, Uniwersyteckie Centrum Pediatrii im. M.Konopnickiej
- Department Name
- Hospital
- Contact Person Name
- Elzbieta Smolewska
- Contact Person Email
- e.smolewska@wp.pl
- Site Name
- Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji, Klinika Reumatologii Wieku Rozwojowego
- Department Name
- Hospital
- Contact Person Name
- Piotr Gietka
- Contact Person Email
- piotr.gietka@spartanska.pl
- Site Name
- Szpital Dzieciecy Sw. Ludwika III Oddział Kliniczny Pediatrii Reumatologii z pododdzialem alergologi
- Department Name
- Hospital
- Contact Person Name
- Zbigniew Zuber
- Contact Person Email
- zbyszekzuber@interia.pl
Spain
- Earliest CTIS Part Ii Submission Date
- 11-03-2024
- Latest Decision Or Authorization Date
- 04-04-2024
- Processing Time Days
- 24
- Number Of Sites
- 6
Sites
- Site Name
- Hospital Infantil Universitario Nino Jesus
- Department Name
- Pediatric Reumatology
- Contact Person Name
- Daniel Clemente
- Contact Person Email
- daniel.clemente@salud.madrid.org
- Site Name
- Hospital Universitario La Paz
- Department Name
- Pediatric Reumatology
- Contact Person Name
- Rosa Alcobendas
- Contact Person Email
- kishinev224@hotmail.com
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Pediatric Reumatology
- Contact Person Name
- Alina Lucica Boteanu
- Contact Person Email
- al_boter@yahoo.com
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Pediatric Reumatology
- Contact Person Name
- Lucia Lacruz Perez
- Contact Person Email
- lacruz_lucper@gva.es
- Site Name
- Sant Joan De Deu Barcelona Hospital
- Department Name
- Pediatric Reumatology
- Contact Person Name
- Jordi Anton
- Contact Person Email
- janton@sjdhospitalbarcelona.org
- Site Name
- Hospital Universitario Ramon Y Cajal (additional entry listed)
- Department Name
- Pediatric Reumatology
Sponsor
Primary sponsor
- Full Name
- Eli Lilly & Co.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Icon Clinical Research Limited
- Name
- Iqvia Rds Inc.
- Name
- Fortrea Inc.
- Name
- Macrostat (Shanghai) Clinical Research Co. Ltd.
Third parties
- {"country":"United States","full_name":"Cleveland Clinic Foundation","duties_or_roles":"Adjudication","organisation_type":"Hospital/Clinic/Other health care facility"}
- {"country":"China","full_name":"Macrostat (Shanghai) Clinical Research Co. Ltd.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United States","full_name":"Fortrea Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"Q2 Solutions","duties_or_roles":"","organisation_type":"Health care"}
- {"country":"United States","full_name":"Signant Health LLC","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
- {"country":"United Kingdom","full_name":"Publicis Healthcare Communications Group Limited","duties_or_roles":"Patient Screening, Recruitment, and/or Retention","organisation_type":"Non-Pharmaceutical company"}
- {"country":"United States","full_name":"Brightech International LLC","duties_or_roles":"","organisation_type":"Health care"}
- {"country":"Italy","full_name":"Pediatric Rheumatology International Trials Organization (PRINTO)","duties_or_roles":"Patient Screening, Recruitment, and/or Retention","organisation_type":"Health care"}
- {"country":"United States","full_name":"Iqvia Rds Inc.","duties_or_roles":"","organisation_type":"Pharmaceutical company"}
Investigational products
- Investigational Product Name
- Baricitinib (oral suspension - paediatric formulation)
- Active Substance
- Baricitinib
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- 1
- Maximum Dose
- 4 mg (maxDailyDoseAmount)
- Investigational Product Name
- BARICITINIB (film-coated tablet)
- Active Substance
- Baricitinib
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- 2
- Maximum Dose
- 4 mg (maxDailyDoseAmount)
- Investigational Product Name
- BARICITINIB (tablet)
- Active Substance
- Baricitinib
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- 1
- Maximum Dose
- 4 mg (maxDailyDoseAmount)
- Investigational Product Name
- BARICITINIB (film-coated tablet - scientific product entry)
- Active Substance
- Baricitinib
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- 2
- Maximum Dose
- 4 mg (maxDailyDoseAmount)
Related trials
Other published trials that may interest you.